acetyl-coa carboxylase 1 (acc1)

CMS-121, a quinolone derivative, is an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage (EC50: 7 nM and 200 nM). CMS-121 shows strong neuroprotective, antioxidative, anti-inflammatory, and renoprotective activities.

CKBA, a derivative of AKBA, acts as an acetyl-CoA carboxylase 1 (ACC1) inhibitor with an IC50 of 5.02 μM. It inhibits Th17 cell differentiation, displaying IC50 values of 3.28 μM in mouse cells and 3.61 μM in human cells. CKBA ointment significantly alleviates psoriasis-like inflammation in mice and can be used for psoriasis research.

CIL56 (CA3) is a small molecule that induces cellular ferroptosis through the production of iron-dependent reactive oxygen species (ROS). It also induces accumulation of long-chain saturated, monounsaturated, and polyunsaturated fatty acids in HT-1080 cells in vitro.HT-1080 cells lacking acetyl-CoA carboxylase 1 (ACC1), the rate-limiting enzyme in fatty acid synthesis, exhibit 5-fold resistance to CIL56 treatment, indicating ACC1 activity sensitizes cells to CIL56-induced cell death.

PF 05175157 is an inhibitor of acetyl-CoA carboxylase 1 (ACC1) and ACC2 (IC50s = 27, 33, 23.5, and 50.4 nM for human ACC1, human ACC2, rat ACC1, and rat ACC2, respectively

Soraphen A ((-)-Soraphen A; Soraphen A1α), a polyketide fungal inhibitor, actively targets acetyl-CoA carboxylase (ACC1) in vivo. It can be isolated from Myxobacter cellulosum [1].